“As we enter into the third year post-launch, we set our sales guidance for 2023 and longer-term projections for Monjuvi in its approved indication to reflect the ongoing and future impact of competitive activity. “Patients living with relapsed or refractory diffuse large B-cell lymphoma continued to benefit from Monjuvi in 2022, as we saw an increase in sales of our medicine in the fourth quarter and a preliminary final sales total in line with our updated guidance,” said Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys. The reduction in Financial Liabilities from Collaborations has no impact on cash. in relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) owed to our partner Incyte. The balance in “Financial Liabilities from Collaborations” reflects an accounting view of expected future profits from the net product sales of Monjuvi in the U.S. Finance income is credited with the difference between the two amounts. net product sales in the range of US$ 80 to 95 million.Īs a result of changes in Monjuvi product sales expectations, the balance sheet item “Financial Liabilities from Collaborations” is reduced from € 580 million (balance as of September 30, 2022) to approximately € 220 million (balance as of Decemunaudited). For the full year of 2023, MorphoSys expects Monjuvi U.S.

Fourth quarter and full year 2022 results will be published on March 15, 2023. net product sales are US$ 25.3 million (€ 24.0 million) for the fourth quarter and US$ 89.4 million (€ 84.9 million) for the full year of 2022.

Preliminary Monjuvi (tafasitamab-cxix) U.S. In this context, MorphoSys reduced its financial liability from the collaboration with Incyte and credited finance income accordingly. net product sales for the full year of 2022 and provided its financial guidance for 2023.

MorphoSys AG (FSE: MOR NASDAQ: MOR) today reported preliminary Monjuvi ® U.S. Preliminary unaudited financial liability from the collaboration with Incyte of approximately € 220 million which represents a reduction of € 360 million.net product sales in the range of US$ 80 to 95 million net product sales of US$ 89.4 million (€ 84.9 million) Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability MorphoSys Reports Preliminary 2022 Monjuvi U.S.

How to set margins in word 2010